Compare AstraZeneca plc (AZN) vs Hims and Hers Health Inc (HIMS) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Hims & Hers Health trades at $34.38, showing no change in the last session. The stock exhibits a bullish technical setup with moving averages supporting upward momentum, while oscillators remain neutral. Recent earnings have been mixed, with Q1 2026 missing expectations, but revenue growth remains positive. Analyst sentiment is divided with a 35% buy rating, and the consensus price target is $33.57. News highlights include expansion in weight-loss treatments and a new JPMorgan receivables facility.

The outlook for HIMS is cautiously optimistic, driven by growth in telehealth and weight-loss segments, but high valuation multiples and recent net income declines pose risks. Investment opportunity lies in market expansion and subscriber growth, while execution risks and competitive pressures require monitoring.